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Summary
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory 
authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an 
interval of 4–12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with 
their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified 
pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy 
of extending the interval between priming and booster doses. In addition, we show the immunogenicity and 
protection afforded by the first dose, before a booster dose has been offered.
Methods We present data from three single-blind randomised controlled trials—one phase 1/2 study in the UK 
(COV001), one phase 2/3 study in the UK (COV002), and a phase 3 study in Brazil (COV003)—and one double-blind 
phase 1/2 study in South Africa (COV005). As previously described, individuals 18 years and older were randomly 
assigned 1:1 to receive two standard doses of ChAdOx1 nCoV-19 (5 × 10¹⁰ viral particles) or a control vaccine or saline 
placebo. In the UK trial, a subset of participants received a lower dose (2·2 × 10¹⁰ viral particles) of the ChAdOx1 
nCoV-19 for the first dose. The primary outcome was virologically confirmed symptomatic COVID-19 disease, 
defined as a nucleic acid amplification test (NAAT)-positive swab combined with at least one qualifying symptom 
(fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia) more than 14 days after the second dose. Secondary 
efficacy analyses included cases occuring at least 22 days after the first dose. Antibody responses measured by 
immunoassay and by pseudovirus neutralisation were exploratory outcomes. All cases of COVID-19 with a NAAT-
positive swab were adjudicated for inclusion in the analysis by a masked independent endpoint review committee. 
The primary analysis included all participants who were SARS-CoV-2 N protein seronegative at baseline, had had at 
least 14 days of follow-up after the second dose, and had no evidence of previous SARS-CoV-2 infection from NAAT 
swabs. Safety was assessed in all participants who received at least one dose. The four trials are registered 
at ISRCTN89951424 (COV003) and ClinicalTrials.gov, NCT04324606 (COV001), NCT04400838 (COV002), and 
NCT04444674 (COV005).
Findings Between April 23 and Dec 6, 2020, 24 422 participants were recruited and vaccinated across the four studies, of 
whom 17 178 were included in the primary analysis (8597 receiving ChAdOx1 nCoV-19 and 8581 receiving control 
vaccine). The data cutoff for these analyses was Dec 7, 2020. 332 NAAT-positive infections met the primary endpoint of 
symptomatic infection more than 14 days after the second dose. Overall vaccine efficacy more than 14 days after the 
second dose was 66·7% (95% CI 57·4–74·0), with 84 (1·0%) cases in the 8597 participants in the ChAdOx1 nCoV-19 
group and 248 (2·9%) in the 8581 participants in the control group. There were no hospital admissions for COVID-19 
in the ChAdOx1 nCoV-19 group after the initial 21-day exclusion period, and 15 in the control group. 108 (0·9%) of 
12 282 participants in the ChAdOx1 nCoV-19 group and 127 (1·1%) of 11 962 participants in the control group had 
serious adverse events. There were seven deaths considered unrelated to vaccination (two in the ChAdOx1 nCov-19 
group and five in the control group), including one COVID-19-related death in one participant in the control group. 
Exploratory analyses showed that vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 after 
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Introduction
The widespread morbidity and mortality associated 
with the 2020 COVID-19 pandemic precipitated the 
most extensive and rapid global vaccine development 
programme in history,1 culminating in the development 
of several vaccines reaching phase 3 efficacy milestones 
and receiving emergency use authorisation by the end of 
that year.2–4 Widespread vaccination programmes have 
commenced in several countries as new vaccines are 
licensed for emergency use by regulators in each setting, 
with a focus primarily on high-risk groups such as the 
elderly, those with comorbidities, or front-line workers.
Vaccine supply is likely to be scarce, at least initially, 
and so policy makers must decide how best to deliver 
available doses to achieve greatest public health benefit, 
and different approaches have been taken in different 
settings. In the UK, second doses of both available 
vaccines (a viral vector and mRNA vaccine) are being 
delivered with an interval of up to 12 weeks,5,6 and this 
regimen is also being considered by several other 
countries.7,8 By contrast, WHO has recently recommended 
a maximum 6 week interval between the two doses of 
the same mRNA vaccine.9
The ChAdOx1 nCoV-19 vaccine (AZD1222) is a 
chimpanzee adenoviral vectored vaccine with full length 
SARS-CoV-2 spike insert, developed at the University of 
Oxford (Oxford, UK). The safety and immunogenicity of 
the vaccine were assessed in four randomised controlled 
trials in the UK, Brazil, and South Africa, and results in 
cohorts of healthy adults and in adults aged 70 years or 
vaccination was 76·0% (59·3–85·9). Our modelling analysis indicated that protection did not wane during this initial 
3-month period. Similarly, antibody levels were maintained during this period with minimal waning by day 90 
(geometric mean ratio [GMR] 0·66 [95% CI 0·59–0·74]). In the participants who received two standard doses, after the 
second dose, efficacy was higher in those with a longer prime-boost interval (vaccine efficacy 81·3% [95% CI 60·3–91·2] 
at ≥12 weeks) than in those with a short interval (vaccine efficacy 55·1% [33·0–69·9] at <6 weeks). These observations 
are supported by immunogenicity data that showed binding antibody responses more than two-fold higher after an 
interval of 12 or more weeks compared with an interval of less than 6 weeks in those who were aged 18–55 years 
(GMR 2·32 [2·01–2·68]).
Interpretation The results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen 
in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in 
exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for 
roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when 
supplies are scarce, while also improving protection after receiving a second dose.
Funding UK Research and Innovation, National Institutes of Health Research (NIHR), The Coalition for Epidemic 
Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D’Or, the Brava and 
Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland’s NIHR Clinical 
Research Network, and AstraZeneca.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
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Research in context
Evidence before this study
The ChAdOx1 nCoV-19 (AZD1222) vaccine was approved for 
emergency use authorisation in the UK on the basis of interim 
efficacy results from 131 cases of primary symptomatic 
COVID-19, with efficacy based on two of the four trials of the 
vaccine. The planned roll-out of the vaccine in the UK involves 
the administration of two doses 12 weeks apart, a policy that 
has received substantial comment.
Added value of this study
This report provides updated primary efficacy results after a 
further month of data collection. The interim report included 
131 cases of primary symptomatic COVID-19. The latest results 
with additional follow-up include 332 cases of primary 
symptomatic COVID-19. Efficacy estimates now include data 
from all four studies of the vaccine from three countries, whereas 
the interim analysis included only two studies in efficacy 
assessments because of the small number of cases in the smaller 
studies. In addition to the primary efficacy assessment, post-hoc 
exploratory analyses have been added, including a breakdown of 
efficacy by prime-boost interval, and the efficacy of a single dose 
of vaccine.
Implications of all the available evidence
The primary analysis supports the findings reported in the interim 
analysis that the vaccine is efficacious and safe. Exploratory 
analyses show that higher vaccine efficacy is obtained with a 
longer prime-boost interval, and that a single dose of vaccine is 
efficacious in the first 90 days, providing further evidence for 
current policy.
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older have been published.4,10–13 Efficacy of two doses of 
the vaccine in the interim analysis of 131 cases (data 
cutoff Nov 4, 2020), which pooled data from Brazil and 
the UK, was 70·4% (95·8% CI 54·8–80·6) overall.4 
ChAdOx1 nCoV-19 was authorised for emergency use in 
the UK on Dec 30, 2020,14 on the basis of the interim 
analysis data,4 based on a regimen of two standard doses 
administered 4–12 weeks apart for adults aged 18 years 
and older, and has since been authorised for use in many 
other countries.
The University of Oxford-sponsored studies were 
initially planned as single-dose studies but were amended 
to incorporate a second dose after review of the phase 1 
immunogenicity data, which showed a substantial 
increase in neutralising antibody with a second dose of 
vaccine.12 After initially providing consent to participate in 
a single-dose study, some participants chose not to receive 
the second dose, providing a self-selected cohort of 
single-dose recipients. Additionally, because of the time 
required to manufacture the second dose, there were 
delays in administration of the second dose for a large 
number of trial participants who received the two-dose 
schedule. These two situations provide an opportunity to 
explore the immunogenicity and efficacy of a single dose 
of vaccine, and the effect of an extended interval before 
delivery of the second dose. In addition, data from an 
additional month of follow-up are now available for 
inclusion in the analysis, providing greater precision in 
estimates because of the larger number of cases for 
analysis in comparison with the previous report.4
Methods
Study design and participants
Data from three single-blind randomised controlled 
trials, one phase 1/2 study in the UK (COV001), 
one phase 2/3 study in the UK (COV002), and a phase 3 
study in Brazil (COV003), and one double-blind phase 1/2 
study in South Africa (COV005) are included in this 
primary analysis because all four trials now meet the 
required criteria for inclusion of having at least five 
primary outcome cases. Full descriptions of the methods 
as well as safety, immunogenicity, and interim efficacy 
analyses of the four studies have been previously 
published in detail, including full study protocols.4,12,13
COV001 (UK) enrolled healthy adults aged 18–55 years. 
COV002 (UK) and COV003 (Brazil) enrolled adults aged 
18 years and older, with a focus on recruitment of health-
care workers and others at increased exposure to 
SARS-CoV-2 infection. COV005 (South Africa) enrolled 
adults aged 18–65 years.
In the UK, the COV001 and COV002 studies were 
approved by the South Central Berkshire Research Ethics 
Committee (COV001 reference 20/SC/0145, March 23, 2020; 
and COV002 reference 20/SC/0179; conditional approval 
April 8, full approval April 19, 2020). The COV003 study 
was approved by the Oxford Tropical Research Ethics 
Committee (OxTREC; reference 36–20, June 12, 2020) 
and by the Comissão Nacional de Ética em Pesquisa 
(June 3, 2020). The COV005 study was approved by 
OxTREC (reference 35-20, June 5, 2020), the University 
of Witwatersand Human Research Ethics committee 
(reference 200501, May 21, 2020), and the South African 
Health Products Regulatory Authority (reference 20200407, 
June 1, 2020).
Randomisation and masking
Briefly, participants in efficacy cohorts from the four trials 
were randomly assigned 1:1 with full allocation 
concealment to receive either ChAdOx1 nCoV-19 vaccine 
or a control product (MenACWY in the UK, MenACWY 
prime and saline boost in Brazil, and saline only in 
South Africa). One group of participants in the COV002 
study in the UK received a low dose as their first dose 
followed by a standard dose, as discussed pre viously.4 
Other participants received two standard doses.
Procedures
Procedures have been described in full previously.4,12,13 At 
baseline, eligibility and medical history was assessed and 
informed consent was taken from all participants. A 
baseline serum sample was taken to assess SARS-CoV-2 
serostatus.
In all studies, participants were asked to contact the 
study site if they had symptoms of COVID-19 and were 
then invited to attend for clinical review and a swab. 
Additionally, in the UK, asymptomatic infections were 
measured by means of weekly self-administered nose 
and throat swabs using kits provided by the Department 
of Health and Social Care as previously described.4 
Those who tested positive on a self-swab were not 
specifically contacted by the study site and they are 
classed as having unknown symptoms in the analysis 
unless specific information was obtained (eg, through 
participants calling their study site) that the participant 
was asymptomatic, or unless the participant had 
additionally reported symptoms and could be classified 
as symptomatic.
Outcomes
The primary outcome was virologically confirmed 
symptomatic COVID-19 disease, defined as a nucleic 
acid amplification test (NAAT)-positive swab combined 
with at least one qualifying symptom (fever ≥37·8°C, 
cough, shortness of breath, anosmia, or ageusia). The 
primary analysis was of cases occurring more than 
14 days after the second dose, with a prespecified 
secondary analysis of cases occurring more than 21 days 
after the first dose.
A secondary analysis of any NAAT-positive case 
included a combination of primary symptomatic cases, 
non-primary symptomatic cases (eg, those who had other 
symptoms not meeting the primary definition such as 
nausea or diarrhoea), asymp tomatic cases, and those with 
unknown symptoms.
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Statistical analysis
The study was powered to include an α-adjusted interim 
analysis triggered when at least 53 cases had accrued 
in participants who had received two standard-dose 
vaccines. This analysis was statistically significant and 
subsequent efficacy results are considered supportive of 
that analysis, with no further adjustment of α.
For the primary analysis, which we present here updated 
with additional cases from an extra month of follow-up, 
participants enrolled in efficacy cohorts were included in 
the analysis according to the vaccine received. Events were 
included that occurred more than 14 days after the second 
dose, in participants who were seronegative to SARS-CoV-2 
N protein at baseline and had at least 14 days of follow-up 
after the second dose and no evidence of SARS-CoV-2 
infection from NAAT swabs before day 14. Vaccine efficacy 
was calculated as 1–the adjusted relative risk (ChAdOx1 
nCoV-19 vs control groups) computed using a robust 
Poisson regression model. The model contained terms for 
study, treatment group, and age group at randomisation. 
The logarithm of the period at risk was used as an offset 
variable in the model to adjust for volunteers having 
different follow-up times during which the events 
occurred. Cumulative incidence of primary symptomatic 
COVID-19 is presented using the Kaplan-Meier method.
We present additional exploratory analyses of single-
dose efficacy, which have been added at the request of 
regulators and policy makers. These are considered as 
supportive analyses to the previously published interim 
efficacy analysis and were not prespecified. The effect of 
the timing of the second dose is explored in more detail.
For the analysis of single-dose efficacy, randomised 
participants enrolled in efficacy cohorts were included in 
the analysis according to the vaccine they received as 
their first dose. Events were included if they occurred 
more than 21 days after the first dose. Participants were 
excluded if they had a NAAT-positive swab in the first 
21 days after the first dose or had fewer than 22 days of 
follow-up. Participants who received a second dose were 
censored in the analysis at the time of their booster dose. 
Participants who did not receive a second dose are 
censored in the analysis at the data cutoff date.
For exploratory analysis, the persistence of anti-spike 
IgG responses after a single dose was measured in the 
UK by standardised ELISA. Decay of antibody over time 
was modelled for low-dose and standard-dose recipients 
using a linear model of log-transformed antibody values. 
A non-linear generalised additive model was also used to 
assess the shape of the decay curve to establish whether 
linear modelling was appropriate. Both models gave 
similar outputs.
Baseline serum samples were measured for nucle o-
capsid reactivity with the Roche Elecsys Anti-SARS-CoV-2 
serology test (PPD Central Laboratories, Zaventem, 
Belgium and Highland Heights, KY, USA) and a 
multiplexed immunoassay (3-plex ECL based assay on the 
MSD platform, PPD Vaccines, Richmond, VA, USA) was 
used to measure the spike-specific response to ChAdOx1 
nCoV-19 vaccination. Antibody neutralisation was 
measured with lentivirus-based pseudo virus particles 
expressing the SARS-CoV-2 spike protein as described.12
For exploratory analyses of the effect of varying the 
timing of the second dose of vaccine, we fit separate 
efficacy models, using unadjusted log-binomial models, 
for each 20-day window starting with a window of 
26–46 days (midpoint for plot 36 days) and increasing by 
1 day for each model. Participants who received their 
second dose within the window were included in that 
model. Vaccine efficacy for each window was plotted 
with 95% CIs. Unadjusted models were used to achieve 
convergence across every model consistently and to 
remove bias from the potentially different effect of 
variation in the distribution of adjustment variables in 
different models. Participants were not randomly assigned 
to their dosing interval and these exploratory analyses 
should be interpreted with caution because it is not 
possible to exclude the possibility that any apparent trend 
is due to measured or unmeasured confounding factors.
To explore the potential for waning of efficacy after the 
first dose before a booster dose was received, a similar 
approach was taken with separate efficacy models fitted 
to 21-day windows of the time from vaccination. Cases 
occurring outside the windows were censored.
Potential differences in population baseline char-
acteristics between those who received a second dose of 
vaccine and those who did not are explored descriptively, 
with comparisons made between groups using χ² tests, 
Wilcoxon rank-sum tests, or Cochran-Armitage tests as 
appropriate.
Safety was assessed in all participants who received at 
least one dose. Safety data were reviewed on an ongoing 
basis by the independent data monitoring safety board. All 
endpoints were adju dicated for inclusion in the analysis 
by an independent masked endpoint review committee.
Data analysis was done using R, version 3.6.1 or later. 
Robust Poisson models were fitted using “proc genmod” 
function in SAS, version 9.4. The four trials are registered 
at ISRCTN89951424 (COV003) and ClinicalTrials.gov, 
NCT04324606 (COV001), NCT04400838 (COV002), and 
NCT04444674 (COV005).
Role of the funding source
AstraZeneca reviewed the data from the study and the 
final manuscript before submission, but the academic 
authors retained editorial control. All other funders of 
the study had no role in the study design, data collection, 
data analysis, data interpretation, or writing of the report.
Results
Between April 23 and Dec 6, 2020, 24 422 partici pants 
were recruited and vaccinated across the four studies, 
of whom 17 178 were included in this primary 
efficacy analysis (8597 receiving ChAdOx1 nCoV-19 
and 8581 receiving control vaccine). 8948 were from the 
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Total cases ChAdOx1 nCoV-19 Control Vaccine efficacy (95% CI)*
Prespecified analyses
Cases more than 14 days after second dose
Primary symptomatic COVID-19 332 84/8597 (1·0%) 248/8581 (2·9%) 66·7% (57·4 to 74·0)
Two standard doses 271 74/7201 (1·0%) 197/7179 (2·7%) 63·1% (51·8 to 71·7)†
Low dose plus standard dose 61 10/1396 (0·7%) 51/1402 (3·6%) 80·7% (62·1 to 90·2)
Asymptomatic or unknown infection 
(COV002 UK only)
130 57/4071 (1·4%) 73/4136 (1·8%) 22·2% (–9·9 to 45·0)
Two standard doses 83 41/2692 (1·5%) 42/2751 (1·5%) 2·0% (–50·7 to 36·2)
Low dose plus standard dose 47 16/1379 (1·2%) 31/1385 (2·2%) 49·3% (7·4 to 72·2)
Any NAAT positive 507 161/8597 (1·9%) 346/8581 (4·0%) 54·1% (44·7 to 61·9)
Two standard doses 390 132/7201 (1·8%) 258/7179 (3·6%) 49·5% (37·7 to 59·0)
Low dose plus standard dose 117 29/1396 (2·1%) 88/1402 (6·3%) 67·6% (50·8 to 78·7)
Exploratory analyses by prime-boost interval
Primary symptomatic COVID-19 cases more than 14 days after second dose
Prime-boost interval (two standard doses)
<6 weeks 111 35/3890 (0·9%) 76/3856 (2·0%) 55·1% (33·0 to 69·9)
6–8 weeks 64 20/1112 (1·8%) 44/1009 (4·4%) 59·9% (32·0 to 76·4)
9–11 weeks 43 11/906 (1·2%) 32/958 (3·3%) 63·7% (28·0 to 81·7)
≥12 weeks 53 8/1293 (0·6%) 45/1356 (3·3%) 81·3% (60·3 to 91·2)
Prime-boost interval (two standard doses or low dose plus standard dose)
<6 weeks 111 35/3905 (0·9%) 76/3871 (2·0%) 55·1% (33·0 to 69·9)
6–8 weeks 64 20/1124 (1·8%) 44/1023 (4·3%) 59·7% (31·7 to 76·3)
9–11 weeks 66 14/1530 (0·9%) 52/1594 (3·3%) 72·2% (50·0 to 84·6)
≥12 weeks 91 15/2038 (0·7%) 76/2093 (3·6%) 80·0% (65·2 to 88·5)
Asymptomatic COVID-19 cases more than 14 days after second dose (COV002 only)
Prime-boost interval (two standard doses)
<6 weeks 17 9/728 (1·2%) 8/733 (1·1%) –11·8% (–189·5 to 56·8)
6–8 weeks 21 14/528 (2·7%) 7/476 (1·5%) –74·2% (–330·3 to 29·5)
9–11 weeks 17 6/599 (1·0%) 11/666 (1·7%) 39·9% (–62·3 to 77·8)
≥12 weeks 28 12/837 (1·4%) 16/876 (1·8%) 22·8% (–63·3 to 63·5)
Prime-boost interval (two standard doses or low dose plus standard dose)
<6 weeks 17 9/728 (1·2%) 8/733 (1·1%) –11·8% (–189·5 to 56·8)
6–8 weeks 21 14/538 (2·6%) 7/488 (1·4%) –75·7% (–334·2 to 28·9)
9–11 weeks 43 17/1223 (1·4%) 26/1302 (2·0%) 31·6% (–26·0 to 62·8)
≥12 weeks 49 17/1582 (1·1%) 32/1613 (2·0%) 47·2% (5·0 to 70·7)
Any NAAT-positive COVID-19 cases more than 14 days after second dose
Prime-boost interval (two standard doses)
<6 weeks 145 51/3890 (1·3%) 94/3856 (2·4%) 47·1% (25·6 to 62·4)
6–8 weeks 90 39/1112 (3·5%) 51/1009 (5·1%) 32·6% (–2·2 to 55·5)
9–11 weeks 68 18/906 (2·0%) 50/958 (5·2%) 61·9% (34·8 to 77·8)
≥12 weeks 87 24/1293 (1·9%) 63/1356 (4·6%) 59·9% (35·8 to 75·0)
Prime-boost interval (two standard doses or low dose plus standard dose)
<6 weeks 145 51/3905 (1·3%) 94/3871 (2·4%) 47·1% (25·6 to 62·4)
6–8 weeks 90 39/1124 (3·5%) 51/1023 (5·0%) 32·2% (–2·7 to 55·3)
9–11 weeks 122 33/1530 (2·2%) 89/1594 (5·6%) 61·8% (43·1 to 74·3)
≥12 weeks 150 38/2038 (1·9%) 112/2093 (5·4%) 65·6% (50·3 to 76·2)
Data are number of cases/number of participants in the group (%), unless otherwise stated. Overall vaccine efficacy and 95% CIs were calculated using robust Poisson models, 
adjusting for study (COV001, COV002, COV003, or COV005) and age group (18–55 years, 56–69 years, or ≥70 years), with an offset for length of time at risk. Models for 
asymptomatic or unknown infections do not adjust for study. Vaccine efficacy and 95% CIs in prime-boost subgroups and for low dose plus standard dose subgroups have 
been calculated using unadjusted robust Poisson models. Any NAAT-positive includes primary symptomatic cases, non-primary symptomatic cases (not shown separately), 
asymptomatic or unknown infections in the UK, and asymptomatic infections in Brazil and South Africa (not shown separately). *Calculated from an unadjusted robust 
Poisson model. †p value for interaction term comparing low dose plus standard dose with two standard doses is p=0·050.
Table 1: Efficacy of ChAdOx1 nCoV-19 more than 14 days after a second dose
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UK trial, 6753 from the Brazil trial, and 1477 from the 
South Africa trial (appendix p 2). Here, we provide safety 
data on 100 958 person-months of follow-up after first 
dose and 49 945 person-months of follow-up after 
two doses. Baseline characteristics were similar for 
vaccine and control groups (appendix p 3). Duration of 
follow-up varied by prime-boost interval (appendix p 4). 
The day for data cutoff for cases to be included in this 
report was Dec 7, 2020.
There were 332 cases of primary symptomatic 
COVID-19 occurring more than 14 days after a booster 
dose, 84 (1·0%) in the 8597 participants in the ChAdOx1 
nCoV-19 group and 248 (2·9%) in the 8581 participants 
in the control group, with overall efficacy of 66·7% 
(95% CI 57·4–74·0; table 1). In the participants who 
received two standard doses, 74 (1·0%) cases occurred in 
the 7201 participants in the ChAdOx1 nCoV-19 group and 
197 (2·7%) in the 7179 in the control group, with vaccine 
efficacy of 63·1% (51·8–71·7). 61 cases were recorded in 
the participants who received a low dose plus standard 
dose, ten (0·7%) of 1396 participants in the ChAdOx1 
nCoV-19 group and 51 (3·6%) of 1402 in the control 
group, with vaccine efficacy of 80·7% (62·1–90·2).
From the day of vaccination, two participants were 
admitted to hospital with COVID-19 in the ChAdOx1 
nCoV-19 group4 (on day 0 and day 10) and 22 in the 
control group, three of whom were considered to have 
severe COVID-19. Vaccine efficacy against COVID-19 
requiring hospital admission from 22 days after the 
first dose was 100% (0 cases in the ChAdOx1 nCoV-19 
group vs 15 cases in the control group), with a lower 
bound of the one-sided 97·5% CI of 72·2% (appendix p 5).
There were 130 cases of asymptomatic infection 
occurring more than 14 days after the booster dose 
(COV002 UK cohort only), with efficacy of 22·2% 
(95% CI –9·9 to 45·0; table 1). In the participants who 
received two standard doses, there was no evidence of 
protection, with vaccine efficacy of 2·0% (–50·7 to 36·2; 
41 cases in the ChAdOx1 nCoV-19 group vs 42 in the control 
group). In the cohort receiving a low dose plus standard 
dose, there were 47 cases and vaccine efficacy was 49·3% 
(7·4 to 72·2; 16 cases vs 31 cases). Efficacy against any 
NAAT-positive infection was 54·1% (44·7 to 61·9), indi-
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Figure 1: Exploratory analysis of vaccine efficacy against primary 
symptomatic COVID-19 more than 14 days after a booster dose, 
by prime-boost interval
(A) All participants who received two doses. (B) Participants who received 
two standard doses. (C) Participants who received a low dose plus standard 
dose. Each datapoint shows one estimate of vaccine efficacy calculated in a 
subset of participants who received two doses of vaccine with a prime-boost 
interval falling within a 20-day interval. The x-axis shows the midpoint of the 
interval such that the first datapoint, plotted at 36 days, includes data from 
participants who received vaccines between 26 and 46 days apart. Estimates are 
from unadjusted log-binomial models. Dotted lines show 95% CIs for each point 
estimate of vaccine efficacy. Bar charts below each plot show the number of 
events included in each efficacy analysis.
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108 (0·9%) of 12 282 participants in the ChAdOx1 
nCoV-19 group and 127 (1·1%) of 11 962 participants in the 
control group had serious adverse events (appendix p 14). 
The most common serious adverse events were infections 
and infestations in 23 (0·2%) participants in the ChAdOx1 
nCoV-19 group and 41 (0·3%) in the control group. The 
adverse event profile was similar across vaccine groups. 
211 (1·7%) of 12 282 participants who received ChAdOx1 
nCoV-19 had a grade 3 adverse event versus 164 (1·4%) of 
11 962 in the control group. Grade 4 adverse events were 
recorded in 48 (0·4%) participants who received ChAdOx1 
nCoV-19 and 34 (0·3%) control participants (appendix 
p 19). There were seven deaths considered unrelated to 
vaccination (two in the ChAdOx1 nCov-19 group and five 
in the control group), including one COVID-19-related 
death in one participant in the control group.
An exploratory analysis modelling the change in 
vaccine efficacy against primary symptomatic COVID-19 
(from 14 days after the second dose) showed that efficacy 
was high after a 2-month prime-boost interval and 
continued to increase with longer dose intervals 
(figure 1A, B). There was less variation in the prime-
boost interval for the low dose plus standard dose cohort, 
with most data accruing in those who had about 3 months 
between first and second doses, and efficacy remained 
high during this period (figure 1C). Vaccine efficacy after 
two standard doses was 55·1% (95% CI 33·0–69·9) with 
an interval of less than 6 weeks and 81·3% (60·3–91·2) 
when more than 12 weeks apart (table 1).
Efficacy against asymptomatic infections in the UK 
showed a similar pattern, with efficacy estimates 
increasing as the interval between doses increased; 
however, the number of cases available for each analysis 
was small within each dose interval bracket and CIs were 
wide (table 1, appendix p 7).
Protection against primary symptomatic COVID-19 
with a single standard dose vaccine was modelled against 
time since first dose. Results showed no evidence of 
waning of protection in the first 3 months after vac-
cination (figure 2A). A single standard dose of vaccine 
provided protection against primary symptomatic 
COVID-19 in the first 90 days with an efficacy of 76·0% 
(95% CI 59·3 to 85·9), but was not efficacious against 
asymptomatic infection over the same time period 
(vaccine efficacy –17·2% [–248·6 to 60·6]; table 2). 
Efficacy of a single standard dose against any 
NAAT-positive infection was 63·9% (46·0 to 75·9) from 
22 days to 90 days, suggesting the potential for a 
substantial reduction in transmission, although these 
results are exploratory and require further investigation.
Participants included in the analysis of a single dose 
were further assessed to identify differences in baseline 
characteristics between those who received a booster dose 
(and are censored in the analysis at that timepoint) and 
those who did not receive a booster dose (and thus 
have longer follow-up). Statistically significant differences 
between these groups were found for age, sex, health or 
social care worker status, dose (low dose plus standard 
dose vs two standard doses), country, ethnicity, and 
follow-up time (all p<0·0001 except ethnicity which was 
p=0·0001; appendix p 6). Participants receiving a booster 
dose were older (median age 40 years [IQR 30–52] in those 
who received a booster dose vs 36 years [28–48] for 
those who did not), with a higher proportion of men 
Figure 2: Exploratory analysis of vaccine efficacy over time from 22 days after a single standard dose ChAdOx1 
nCoV-19 (A) and persistence of anti-SARS-CoV-2 spike IgG by standardised ELISA antibody after a single dose 
of either standard-dose or low-dose vaccine (B) 
(A) Each datapoint shows one estimate of vaccine efficacy calculated in a subset of participants who were followed 
up during a 21-day period after their first dose (n=18 548). Datapoints are plotted on the x-axis at the midpoint of 
the follow-up period. For each estimate of vaccine efficacy, cases were censored if they occurred before or after the 
21-day period, such that the first datapoint, plotted at 33 days, shows vaccine efficacy in the 3 weeks from 22 days 
to 43 days after vaccination. Lines show 95% CIs for each point estimate of vaccine efficacy. The bar chart shows the 
number of participants with COVID-19 included in each model. Data are also in table 2. (B) Solid lines show 
estimates from a linear model with shaded areas showing SEs. Samples included are from participants given a single 
dose in study COV001 who had a blood sample taken at 6 months (n=44), and participants in COV002 who had a 
blood sample taken at the time of their booster dose (n=264). Timings for booster doses varied. All participants had 
blood taken at day 28. Because of laboratory capacity, samples from all participants in the trial have not all been 
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(8471 [44·2%] of 19 150 vs 1072 [39·0%] of 2752) and non-
white participants (4615 [24·1%] of 19 150 vs 571 [20·8%] 
of 2751), and a smaller proportion of health or social care 
workers (11 518 [60·1%] of 19 150 vs 1809 [65·7%] of 2752) 
compared with those who did not receive a booster dose. 
A smaller proportion of UK COV002 participants who 
received a booster dose received a low-dose prime 
vaccination (2894 [33·4%] of 8676 participants) than in 
those who did not receive a booster (480 [40·9%] of 1173). 
Follow-up time differed between the two groups, as 
expected because of the censoring of participants at the 
time of booster dose (median time 20 days [IQR 10·0–58·0] 
in those receiving a booster dose vs 90 days [23·0–157·0] 
in those who did not). Adjustment for baseline factors did 
affect vaccine efficacy estimates (appendix p 6).
Anti-SARS-CoV-2 spike IgG responses to a single dose 
of vaccine measured by standardised ELISA decayed log-
linearly over a 6-month period. Geometric mean antibody 
decay estimated in a linear model showed a decrease 
from the peak at day 28, of 34% by day 90 (geometric 
mean ratio [GMR] 0·66 [95% CI 0·59–0·74]) and by 
64% by day 180 (GMR 0·36 [0·27–0·47]; figure 2B).
Participants aged 18–55 years who received a 
second standard vaccine more than 12 weeks after the 
first had antibody titres more than two-fold higher than 
those who received the second dose within 6 weeks of 
their initial vaccination (GMR 2·32 [95% CI 2·01–2·68]; 
figure 3; appendix pp 9–10). Similarly, neutralising 
antibody titres measured by pseudovirus were higher 
after a longer interval before the second dose (appendix 
p 11).
Plotting anti-SARS-CoV-2 spike IgG against vaccine 
efficacy for each dose interval showed evidence of a 
potential relationship between binding antibody and 
vaccine protection, as well as between neutralisation 
anti body and vaccine efficacy, suggesting potential 
correlates of protection (figure 4).
Kaplan-Meier cumulative incidence of primary 
symptomatic COVID-19 showed clear differentiation 
between ChAdOx1 nCoV-19 and control groups, with 
non-overlapping confidence intervals, in line with 
efficacy estimates (appendix pp 12–13).
Discussion
Here, we report a prespecified full primary analysis of 
the efficacy of the ChAdOx1 nCoV-19 vaccine more than 
14 days after a second dose, with 332 symp tomatic cases 
of COVID-19 in an analysis population of 17 178 study 
participants and an efficacy of 66·7% (95% CI 57·4–74·0), 
confirming the results of our published interim analysis4 
(131 cases reported in the interim analysis). In this 
updated analysis, there were no additional hospital 
admissions or cases of severe COVID-19 in the ChAdOx1 
nCoV-19-vaccinated group after the initial 21-day period 
after vaccination, compared with 15 in the control group. 
These new analyses provide impor tant verification of 
the interim data that underpinned the emergency use 
Total cases ChAdOx1 nCoV-19 Control Vaccine efficacy (95% CI)
Primary symptomatic COVID-19 cases more than 21 days after a single standard dose
Time since first standard dose
22 to 30 days 37 7/9257 (0·1%) 30/9237 (0·3%) 76·7% (47·0 to 89·8)
31 to 60 days 28 6/7147 (0·1%) 22/7110 (0·3%) 72·8% (32·9 to 89·0)
61 to 90 days 23 4/2885 (0·1%) 19/2974 (0·6%) 78·3% (36·4 to 92·6)
91 to 120 days 10 4/1369 (0·3%) 6/1404 (0·4%) 31·6% (–141·8 to 80·7)
22 to 90 days 88 17/9257 (0·2%) 71/9237 (0·8%) 76·0% (59·3 to 85·9)
Asymptomatic COVID-19 infections more than 21 days after a single standard dose (UK COV002 only)
Time since first dose
22 to 30 days 6 3/3236 (0·1%) 3/3239 (0·1%) –0·1% (–395·4 to 79·8)
31 to 60 days 6 4/2703 (0·1%) 2/2687 (0·1%) –100·1% (–992·2 to 63·3)
61 to 90 days 1 0/1843 (0·0%) 1/1891 (0·1%) ··
91 to 120 days 4 1/780 (0·1%) 3/765 (0·4%) 67·6% (–210·8 to 96·6)
22 to 90 days 13 7/3236 (0·2%) 6/3239 (0·2%) –17·2% (–248·6 to 60·6)
Any NAAT-positive COVID-19 infections more than 21 days after a single standard dose
Time since first dose
22 to 30 days 51 14/9257 (0·2%) 37/9237 (0·4%) 62·3% (30·2 to 79·6)
31 to 60 days 46 14/7147 (0·2%) 32/7110 (0·5%) 56·3% (18·2 to 76·7)
61 to 90 days 24 4/2885 (0·1%) 20/2974 (0·7%) 79·4% (39·8 to 93·0)
91 to 120 days 17 7/1369 (0·5%) 10/1404 (0·7%) 28·2% (–88·1 to 72·6)
22 to 90 days 121 32/9257 (0·3%) 89/9237 (1·0%) 63·9% (46·0 to 75·9)
Data are number of cases/number of participants in the group (%), unless otherwise specified. Vaccine efficacy and 
95% CIs were calculated via unadjusted robust Poisson models. Participants were censored in the analysis at the upper 
limit of the time window. Any NAAT-positive includes primary symptomatic cases, non-primary symptomatic cases 
(not shown separately), asymptomatic or unknown infections in the UK, and asymptomatic infections in Brazil and 
South Africa (not shown separately).
Table 2: Efficacy of ChAdOx1 nCoV-19 more than 21 days after a single dose
Figure 3: Anti-SARS-CoV-2 spike IgG responses by multiplex immunoassay at 28 days after the second 
dose in participants receiving two standard doses or low dose plus standard dose, by prime-boost 
interval (n=3337)
Participants who were NAAT positive before the blood sample taken at day 28 were not included in the analyses. 
About 15% of samples from participants were analysed using this assay. The midlines of the boxes show medians 
and the outer bounds of the boxes show IQRs. Error bars show 1·5 × the IQR above or below the 75th or 
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authorisation of the vaccine in the UK by the Medicines 
and Healthcare products Regulatory Agency (MHRA) on 
Dec 30, 2020,14 and other international regulators since 
the end of 2020, including the European Medicines 
Agency and regulators in India, Nepal, Bangladesh, 
Argentina, Brazil, and Mexico.
The analysis presented here provides strong evidence 
for the efficacy of two standard doses of the vaccine, 
which is the regimen approved by the MHRA and other 
regulators. Following regulatory approval, a key question 
for policy makers to plan the optimal approach for roll-
out is the optimal dose interval, which is assessed in this 
report through post-hoc exploratory analyses. Two criteria 
that contribute to decision making in this area are the 
effect of prime-boost interval on protection after the 
second dose and the degree to which the vaccinated 
individual is at risk of infection during the time period 
before the booster dose, if there were either reduced 
efficacy with a single dose or rapid waning of efficacy 
before the second vaccination.
Exploratory analyses are presented in this report that 
show protection with dosing intervals from less than 
6 weeks to 12 weeks or more and that a longer interval 
provides better protection after a booster dose without 
compro mising protection in a 3-month period before the 
second dose is administered.
In exploratory analyses, a single standard dose of 
ChAdOx1 nCoV-19 had an efficacy of 76·0% (95% CI 
59·3 to 85·9) against symptomatic COVD-19 in the first 
90 days after vaccination, with no significant waning of 
protection during this period. It is not clear how long 
protection might last with a single dose because follow-up 
is limited to the time periods described here, and, for this 
reason, a second dose of vaccine is recommended.
A second dose of ChAdOx1 nCoV-19 induces increased 
neutralising antibody levels10,12 and is probably necessary 
for long-lasting protection. However, where there is low 
supply of vaccine, a policy of initially vaccinating a larger 
cohort with a single dose might provide better overall 
population protection than vaccinating half the number 
of individuals with two doses in the short term. With 
the evidence available at this time, it is anticipated that a 
second dose is still required to potentiate long-lived 
immunity. Recent modelling of delayed boosting suggests 
that even in the presence of substantial waning of 
first-dose efficacy, programmes that delay a second dose 
to vaccinate a larger proportion of the population result in 
greater immediate overall population protection.15
In our study, vaccine efficacy after the second dose was 
higher in those with a longer prime-boost interval, 
reaching 81·3% in those with a dosing interval of 12 weeks 
or more versus 55·1% in those with an interval of less 
than 6 weeks. Point estimates of efficacy were lower with 
shorter dosing intervals, although it should be noted that 
there is some uncertainty because the CIs overlap. Higher 
binding and neutralising antibody titres were observed in 
sera with the longer prime-boost interval, suggesting that, 
assuming there is a relationship between the humoral 
immune response and efficacy, these might be true 
findings and not artifacts of the data. Greater protective 
efficacy associated with stronger immune responses after 
a wider prime-boost interval have been seen with other 
vaccines such as those for influenza, Ebola virus disease, 
and malaria.16–18 The findings presented here for the 
ChAdOx1 nCoV-19 vaccine are consistent with policy 
recommendations in different countries to use dose 
intervals of 4–12 weeks for this vaccine.
The slightly lower vaccine efficacy against symptomatic 
COVID-19 of 66·7% after a booster dose appears counter-
intuitive compared with the 76% efficacy after a single 
dose, although these differences are non-significant. 
Cases included in single-dose estimates occurred earlier 
in the year than those included in post-second-dose 
analyses, and the intensity of the epidemics varied in the 
Figure 4: Relationship between binding and neutralising antibody 28 days 
after second dose, and vaccine efficacy against primary symptomatic 
COVID-19
Vaccine efficacy with 95% CI against primary symptomatic COVID-19 in 
participants who received two standard doses and those who received a low 
dose plus standard dose combined are shown plotted against the GMT (95% CI) 
of anti-SARS-CoV-2 spike IgG from an immunoassay (A), and the GMT (95% CI) 
pseudovirus neutralisation (B), for each prime boost interval. GMT=geometric 
meant titre.
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different countries, making single-dose and two-dose 
estimates difficult to directly compare with each other.
In our interim analysis, we identified a higher efficacy 
in a subgroup analysis of those who received the low 
dose plus standard dose regimen.4 This finding is 
supported by the results of this analysis, although these 
findings are exploratory. With further data available, we 
show that the enhanced immunogenicity and efficacy 
with this regimen might be partly driven by the longer 
dosing interval that was a feature of this subgroup, 
further supporting the observation of a relationship 
between dose interval and efficacy in those who received 
two standard doses. The two standard doses regimen is 
preferred operationally because it is more straightforward 
to deliver the same vaccine for both doses and because 
there are more immunogenicity and efficacy data to 
support its use.
A further important question is whether vaccines can 
reduce transmission, and therefore combined with 
physical distancing measures contribute to reductions in 
human-to-human transmission of the virus. Although 
transmission studies were not included in the analysis, 
swabs were obtained from volunteers every week in the 
UK study, regardless of symptoms, to allow assessment of 
the overall effect of the vaccine on risk of infection, and 
thus a surrogate for potential onward transmission. If 
there was no effect of a vaccine on asymptomatic infection 
(about a third of infections), it would be expected that an 
efficacious vaccine would simply convert severe cases to 
mild cases and mild cases to asymptomatic, with overall 
NAAT positivity unchanged. Overall NAAT positivity is 
appropriate to assess whether there is a reduction in the 
burden of infection. We showed that a single standard 
dose of the vaccine had efficacy against any NAAT-positive 
infection, including symptomatic and asymptomatic 
infec tions, of 63·9% between day 22 and 90 after first 
dose, and that, after the second dose, the two standard 
doses schedule had an efficacy of 49·5%. These data 
indicate that ChAdOx1 nCoV-19, used in the authorised 
schedules, might have a substantial effect on transmission 
by reducing the number of infected individuals in the 
population. Notably, asymptomatic infections were only 
measured in the UK. Vaccine efficacy against any NAAT-
positive infection after a second dose appears lower than 
single-dose efficacy, probably because of the larger 
proportion of UK cases in the analysis and therefore the 
larger number of asymptomatic infections included, for 
which efficacy is lower.
No correlate of protection has yet been defined for 
COVID-19 vaccines; however, the data presented here on 
the relationship between antibody levels and efficacy 
suggest that humoral immunity might play a role. By 
contrast, high protective efficacy recorded early after a 
single dose of vaccine in this study, and also seen with 
other vaccines from different manufacturers,3 suggests 
other immunological mechanisms might be at play early 
after the first dose, because lower levels of neutralising 
antibody are detected after a single dose. Further study of 
correlates of protection is ongoing.
There are some limitations to the analyses presented in 
this report. The studies were not designed to establish 
whether vaccine efficacy differed by dose interval and the 
presence of data of varying intervals arose because of 
the logistics of running large-scale clinical trials in a 
pandemic setting. These are therefore post-hoc explora-
tory analyses only with potential for multiple sources of 
bias, and were not prespecified. However, the analyses 
are presented here to provide a rigorous peer-reviewed 
interrogation of updated data that reflect the approach 
that is currently being used to underpin the deployment 
of ChAdOx1 nCoV-19 in the response to the pandemic. 
The previous interim analysis was carefully considered 
by regulators and policy makers and is aligned with the 
findings presented here.
In our data, the length of follow-up after the second dose 
was short and follow-up tends to be longer in those who 
were boosted early and thus have shorter prime-boost 
intervals. Furthermore, the participants who contribute 
to the analysis of single-dose efficacy are a mixture of 
participants with events occurring before their booster 
dose and participants who did not receive a booster dose. 
These two cohorts differ in some key characteristics; 
participants who received a booster dose were slightly 
younger, a greater proportion were men, and a smaller 
proportion were white compared with those who did not 
receive a booster dose.
It is not clear what effect each of these individual 
sources of variation in the data have on vaccine efficacy 
estimates. However, the same trend seen with efficacy is 
also seen in the immunological data, suggesting an 
underlying biological mechanism.
 Vaccination programmes aimed at vaccinating a large 
proportion of the population with a single dose, with a 
second dose given after a 3-month period, might be an 
effective strategy for reducing disease, and might have 
advantages over a programme with a short prime-boost 
interval for roll-out of a pandemic vaccine when supplies 
are scarce in the short term. Two doses of ChAdOx1 
nCoV-19 was efficacious in preventing symptomatic 
COVID-19. These results confirm those seen in the 
interim analysis of the trials.
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